M15-562: A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Safety, Pharmacokinetic, and Preliminary Efficacy of ABBV-8E12 in Progressive Supranuclear Palsy

Grants and Contracts Details

StatusFinished
Effective start/end date4/18/17 → 10/23/20

Funding

  • AbbVie Incorporated: $390,271.00